Literature DB >> 16912190

Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation.

Sanjeev Das1, Pat P Ongusaha, Yoon Sun Yang, Jin-Mo Park, Stuart A Aaronson, Sam W Lee.   

Abstract

Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by various types of collagens and is known to play a role in cell attachment, migration, survival, and proliferation. However, little is known about the molecular mechanism(s) underlying the role of DDR1 in cancer. We report here that DDR1 induces cyclooxygenase-2 (Cox-2) expression resulting in enhanced chemoresistance. Depletion of DDR1-mediated Cox-2 induction using short hairpin RNA (shRNA) results in increased chemosensitivity. We also show that DDR1 activates the nuclear factor-kappaB (NF-kappaB) pathway and blocking this activation by an I kappaB superrepressor mutant results in the ablation of DDR1-induced Cox-2, leading to enhanced chemosensitivity, indicating that DDR1-mediated Cox-2 induction is NF-kappaB dependent. We identify the upstream activating kinases of the NF-kappaB pathway, IKK beta and IKK gamma, as essential for DDR1-mediated NF-kappaB activation, whereas IKK alpha seems to be dispensable. Finally, shRNA-mediated inhibition of DDR1 expression significantly enhanced chemosensitivity to genotoxic drugs in breast cancer cells. Thus, DDR1 signaling provides a novel target for therapeutic intervention with the prosurvival/antiapoptotic machinery of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912190     DOI: 10.1158/0008-5472.CAN-06-1215

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts.

Authors:  Pedro A Ruiz; Gabor Jarai
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

Review 2.  Discoidin domain receptor tyrosine kinases: new players in cancer progression.

Authors:  Rajeshwari R Valiathan; Marta Marco; Birgit Leitinger; Celina G Kleer; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

Review 3.  Discoidin domain receptors: a proteomic portrait.

Authors:  Leo K Iwai; Maciej T Luczynski; Paul H Huang
Journal:  Cell Mol Life Sci       Date:  2014-04-05       Impact factor: 9.261

4.  Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy.

Authors:  Dominique Guerrot; Monique Kerroch; Sandrine Placier; Sophie Vandermeersch; Claire Trivin; Mouna Mael-Ainin; Christos Chatziantoniou; Jean-Claude Dussaule
Journal:  Am J Pathol       Date:  2011-05-13       Impact factor: 4.307

5.  Discoidin domain receptor 1: New star in cancer-targeted therapy and its complex role in breast carcinoma.

Authors:  Hui Jing; Jingyuan Song; Junnian Zheng
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

6.  Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells.

Authors:  Luis Castro-Sanchez; Adriana Soto-Guzman; Margarita Guaderrama-Diaz; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

7.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

Review 8.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

9.  Design and Optimization of 3'-(Imidazo[1,2-a]pyrazin-3-yl)-[1,1'-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors.

Authors:  Cheng Mo; Zhang Zhang; Yupeng Li; Minhao Huang; Jian Zou; Jinfeng Luo; Zheng-Chao Tu; Yong Xu; Xiaomei Ren; Ke Ding; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2020-01-06       Impact factor: 4.345

10.  A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.

Authors:  Jose I Martin-Subero; Ole Ammerpohl; Marina Bibikova; Eliza Wickham-Garcia; Xabier Agirre; Sara Alvarez; Monika Brüggemann; Stefanie Bug; Maria J Calasanz; Martina Deckert; Martin Dreyling; Ming Q Du; Jan Dürig; Martin J S Dyer; Jian-Bing Fan; Stefan Gesk; Martin-Leo Hansmann; Lana Harder; Sylvia Hartmann; Wolfram Klapper; Ralf Küppers; Manuel Montesinos-Rongen; Inga Nagel; Christiane Pott; Julia Richter; José Román-Gómez; Marc Seifert; Harald Stein; Javier Suela; Lorenz Trümper; Inga Vater; Felipe Prosper; Claudia Haferlach; Juan Cruz Cigudosa; Reiner Siebert
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.